gained more than 9% Monday after the company said its drug Proellex significantly reduced pain in patients with endometriosis.
Shares rose 56 cents to $6.73.
Trials comparing the drug with the commonly used treatment Lucrin, also known as Lupron, showed that Proellex significantly reduced the duration and severity of pain when used at its highest tested dose of 50 milligrams. Patients in the study maintained diaries of their symptoms and filled out questionnaires on their levels of pain. Endometriosis is one of the most common causes of pelvic pain and infertility in women.
On average, women treated with 50 mg Proellex reported 85.5 pain-free days during three months of treatment, or 95% of study days, compared with 61 pain-free days, or 67.8% of study days, reported by patients on Lucrin.
The drug was less effective at lower doses. Patients receiving 25 milligrams and 12.5 milligrams of Proellex saw a dose-dependent reduction in pain, with 71.9% and 49.4% of study days pain free, the company reported in a press release Monday. Women treated with the highest dose also reported a significant reduction in pain-associated distress after three months, with only one woman reporting mild distress.
"Although these data are only reflective of three months of treatment, we are enthusiastic about the significance of these data," said Joseph Podolski, CEO of Repros. "The endometriosis market is large and remains underserved. Few drug therapies are viable for long-term use, leaving invasive laparoscopy as the most common treatment."
The company said it hired Dr. Andre van As as its chief medical officer. Van As has 40 years of medical experience, including 16 years in the pharmaceutical industry, most recently serving in senior clinical and regulatory positions at